Search results
Results from the WOW.Com Content Network
In February 2021, the FDA issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in people twelve years of age or older weighing at least 40 kilograms (88 lb) who test positive for SARS‑CoV‑2 and who are at high risk for progressing to severe COVID-19.
On 9 February 2021, the FDA issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in people twelve years of age or older weighing at least 40 kilograms (88 lb) who test positive for SARS‑CoV‑2 and who are at high risk for progressing to severe COVID ...
In January 2021, the United States agreed to purchase 1.25 million doses of the drug for $2.625 billion, at $2,100 per dose. [29] [30] On 14 September, another 1.4 million doses were purchased for the same price, totaling $2.94 billion. [31] In January 2021, the German government purchased 200,000 doses for €400 million at €2,000 per dose. [32]
AD5-nCOV, trade-named Convidecia, is a single-dose [2] viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics , with Phase III trials conducted in Argentina , [ 3 ] Chile , [ 4 ] Mexico , [ 5 ] Pakistan , [ 6 ] Russia , [ 7 ] and Saudi Arabia [ 8 ] with 40,000 participants.
Russia commits to deliver the first doses of Gamaleya's Sputnik V COVID-19 vaccine to the Philippines around April 2021. The Philippines and Russia are also negotiating regarding a plan to set up a production facility for Sputnik V vaccines in the Philippines. [124] The first batch of Gamaleya's vaccine, consisting of 15,000 doses, arrived on ...
The phase II concluded in April 2021. [12] [13] [14] In April 2021, the Drugs Controller General of India permitted the vaccine candidate to start phase III clinical trials. A total of 1,268 healthy participants between the age of 18 and 80 years to be selected from 15 sites across India for the trial and intended to be part of a larger global ...
The GSK adjuvant is intended to enhance the immune response to CoVLP, reducing the amount of antigen required per dose, thereby facilitating mass production of vaccine doses. [ 18 ] [ 19 ] In March 2022, the vaccine was rejected by the World Health Organization due to the tobacco company Philip Morris International owning a stake in Medicago ...
The country also reduces domestic flights to once per day, and international flights to twice per week for domestic airlines and once per week for foreign airlines. COVID-19 pandemic in Peru. Peru launches a vaccination program against COVID-19 two days after it received 300,000 doses of Sinopharm's BBIBP-CorV vaccine.